Kindred Biosciences, Inc.
KIN
KIN was delisted on the 27th of August, 2021.
41 hedge funds and large institutions have $64.1M invested in Kindred Biosciences, Inc. in 2016 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 12 increasing their positions, 15 reducing their positions, and 3 closing their positions.
24% more capital inflows, than outflows
Capital inflows: $1.77M | Capital outflows: $1.43M
0.21% more ownership
Funds ownership: 64.37% → 64.58% (+0.21%)
7% less funds holding
Funds holding: 44 → 41 (-3)
20% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 15
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$873K |
| 2 |
Ariel Investments
Chicago,
Illinois
|
+$590K |
| 3 |
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
+$137K |
| 4 |
Renaissance Technologies
New York
|
+$122K |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$16.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$833K |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$480K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$33.8K |
| 4 |
Goldman Sachs
New York
|
-$19.9K |
| 5 |
Morgan Stanley
New York
|
-$15.3K |
KIN Hedge Fund Activity: Q3 2016 in Review
41 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Kindred Biosciences, Inc. (KIN) for Q3 2016, worth a combined $64.1M — up 41% from $45.3M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of KIN and 0 opened new positions — a net loss of 3 holders — while 15 trimmed existing stakes and 12 added.
The largest buyer was Wells Fargo, adding an estimated $873K. The largest seller was JP Morgan Chase, exiting entirely with an estimated $833K sold.
- 41 institutional investors held Kindred Biosciences, Inc. (KIN) as of Q3 2016, down from 44 in Q2 2016.
- Funds reported $64.1M of Kindred Biosciences, Inc. stock for Q3 2016, up 41% quarter-over-quarter.
- 0 funds opened new Kindred Biosciences, Inc. positions in Q3 2016 and 3 closed out, a net change of -3 holders.
- The largest Kindred Biosciences, Inc. buyer in Q3 2016 was Wells Fargo, an estimated $873K added.
- The largest Kindred Biosciences, Inc. seller in Q3 2016 was JP Morgan Chase, an estimated $833K sold.
Based on aggregated 13F filings for Q3 2016.